Profile change history

What changed for Albiglutide?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Albiglutide identity.

19Total events
19Record additions
0Version changes
8Cited source years

Collection chronology

Evidence added to PeptideScanner

Browse all 19 connected records →

Showing the latest 19 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 17, 2026.

Record added

Federal Register notice 2016-13797

The Federal Register published notice 2016-13797, attributed to FDA and its parent HHS department, on 2016-06-10. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TANZEUM,” and PeptideScanner's exact reviewed identity mapping connects the document to Albiglutide.

PeptideScanner change date
November 17, 2026
Cited source date
June 10, 2016
Evidence lane
Regulatory
Record added

ClinicalTrials.gov record NCT00838903

PeptideScanner retained ClinicalTrials.gov record NCT00838903 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.

PeptideScanner change date
November 16, 2026
Cited source date
January 9, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00838916

PeptideScanner retained ClinicalTrials.gov record NCT00838916 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.

PeptideScanner change date
November 16, 2026
Cited source date
January 9, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00839527

PeptideScanner retained ClinicalTrials.gov record NCT00839527 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.

PeptideScanner change date
November 16, 2026
Cited source date
January 9, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00849017

PeptideScanner retained ClinicalTrials.gov record NCT00849017 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.

PeptideScanner change date
November 16, 2026
Cited source date
January 9, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00849056

PeptideScanner retained ClinicalTrials.gov record NCT00849056 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.

PeptideScanner change date
November 16, 2026
Cited source date
January 9, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00938158

PeptideScanner retained ClinicalTrials.gov record NCT00938158 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-07-21, and PeptideScanner's reviewed identity mapping was albiglutide.

PeptideScanner change date
November 16, 2026
Cited source date
July 21, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01077505

PeptideScanner retained ClinicalTrials.gov record NCT01077505 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-14, and PeptideScanner's reviewed identity mapping was albiglutide.

PeptideScanner change date
November 16, 2026
Cited source date
June 14, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01098461

PeptideScanner retained ClinicalTrials.gov record NCT01098461 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-13, and PeptideScanner's reviewed identity mapping was albiglutide.

PeptideScanner change date
November 16, 2026
Cited source date
January 13, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01098539

PeptideScanner retained ClinicalTrials.gov record NCT01098539 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-02-28, and PeptideScanner's reviewed identity mapping was albiglutide.

PeptideScanner change date
November 16, 2026
Cited source date
February 28, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01406262

PeptideScanner retained ClinicalTrials.gov record NCT01406262 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-08, and PeptideScanner's reviewed identity mapping was albiglutide.

PeptideScanner change date
November 16, 2026
Cited source date
June 8, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01475734

PeptideScanner retained ClinicalTrials.gov record NCT01475734 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-11, and PeptideScanner's reviewed identity mapping was albiglutide.

PeptideScanner change date
November 16, 2026
Cited source date
January 11, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01777282

PeptideScanner retained ClinicalTrials.gov record NCT01777282 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-05-03, and PeptideScanner's reviewed identity mapping was albiglutide.

PeptideScanner change date
November 16, 2026
Cited source date
May 3, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02229227

PeptideScanner retained ClinicalTrials.gov record NCT02229227 at 2026-11-16T17:45:42.793Z. Its registry update date was 2020-11-27, and PeptideScanner's reviewed identity mapping was albiglutide.

PeptideScanner change date
November 16, 2026
Cited source date
November 27, 2020
Evidence lane
Clinical trials
Record added

Apremilast, albiglutide, and empagliflozin.

PubMed lists PMID 25216888 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2014 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
June 15, 2015
Evidence lane
Literature metadata
Record added

Albiglutide for the treatment of type 2 diabetes mellitus.

PubMed lists PMID 28085780 in The Nurse practitioner as Journal Article, with publication-date metadata of 2017-02-12 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
July 18, 2019
Evidence lane
Literature metadata
Record added

Albiglutide (Tanzeum) for Diabetes Mellitus.

PubMed lists PMID 28409609 in American family physician as Journal Article, Review, with publication-date metadata of 2017-04-15 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 15, 2018
Evidence lane
Literature metadata
Record added

Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.

PubMed lists PMID 32219329 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2020-06-01 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
February 1, 2021
Evidence lane
Literature metadata